|
Catalent targets biosimilars with UMN Pharma
February 2013
SHARING OPTIONS:
SOMERSET, N.J.—An agreement has been inked between Catalent
Pharma Solutions and UMN Pharma
Inc. to provide UMN Pharma with a range of
biosimilar cell lines through the use of Catalent's proprietary GPEx
technology. Per the agreement, UMN
and its subsidiary UNIGEN will produce
biosimilars using Catalent's GPEx cell lines. Separately, UMN Pharma will
assemble an alliance of
pharmaceutical companies for product development,
including clinical trials, marketing and sales, and plans to begin several
biosimilar projects with
the allied companies for the Asian market.
"There are great synergies between UMN Pharma and Catalent
in terms of technologies, business structure, speed and culture. Harnessing
Catalent's broad biologics development and cell construction expertise
gives
UMN Pharma a unique platform to grow our biosimilars business globally," said
Masahiro Michishita, executive chairman of UMN Pharma. Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|